Advanced Blends
KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Repair Immunity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 80 mg
Dosing window: Anytime
Receptor / target: VEGFR2; G-Actin; MMP; Alpha-MSH
Properties: Dopamine Buffer
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 3.2mg daily | Yields exactly 2.0mg GHK-Cu, and 400mcg each of BPC-157, TB-500, and KPV. 5 days on, 2 days off (skip weekends). |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 2 mg 1x Daily | Yields 250mcg each TB-500, BPC-157, & KPV, plus 1.25mg GHK-Cu. |
| Weeks 3-4 | 4 mg 1x Daily | Yields 500mcg each TB-500, BPC-157, & KPV, plus 2.5mg GHK-Cu. |
| Weeks 5-8 | 6 mg 1x Daily | Yields 750mcg each TB-500, BPC-157, & KPV, plus 3.75mg GHK-Cu. |
| Weeks 9-12 | 4 mg 1x Daily | Yields 500mcg each TB-500, BPC-157, & KPV, plus 2.5mg GHK-Cu. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 3 mg 1x Daily | Yields 375mcg each TB-500, BPC-157, & KPV, plus 1.87mg GHK-Cu. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Blend protocols have to pass every ingredient's logic, not just the headline goal. If one ingredient conflicts with a condition, medication, or selected compound, the blend recommendation changes. Entry context: target (VEGFR2; G-Actin; MMP; Alpha-MSH); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. For blends, the highest-risk ingredient sets the caution level.
Independent evidence
Independent safety notes: No approved-label dosing was identified for this combined blend. | FDA lists BPC-157 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information for proposed routes. | FDA lists TB-500 (thymosin beta-4 fragment LKKTETQ) among withdrawn nominated bulk substances with no identified human exposure data. | FDA states it has not identified human exposure data for KPV administered by any route. | FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data.
Regulatory status: not approved multi compound blend component warnings
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer: BPC-157's VEGFR2-mediated angiogenic activity and GHK-Cu's comprehensive pro-growth gene program upregulation are absolutely contraindicated in active malignancy for the same reasons as GLOW; KPV's MC receptor-mediated anti-inflammatory activity in the tumor microenvironment is an additional consideration since tumor-associated inflammation suppression could theoretically reduce immune surveillance of the tumor. Limited / unverified
- Zinc deficiency: GHK-Cu copper competition with zinc absorption applies identically to KLOW as to GLOW; zinc status must be confirmed and repleted before initiating KLOW; concurrent zinc supplementation (15-30mg/day) is required throughout all KLOW cycles. Limited / unverified
- Wilson's disease: copper metabolism disorder; GHK-Cu copper delivery is absolutely contraindicated. Limited / unverified
- Active autoimmune disease in acute flare: KPV's MC receptor-mediated anti-inflammatory activity produces immune modulation; in some autoimmune conditions, the NF-κB suppression is beneficial (IBD, psoriasis, skin inflammation); in others (systemic lupus, vasculitis, severe rheumatoid arthritis flare), the interaction between KPV's immune modulation and the existing dysregulated immune response requires medical supervision and monitoring. Limited / unverified
- Concurrent immunosuppressive therapy (calcineurin inhibitors, biologics for autoimmune disease, post-transplant immunosuppression): KPV's MC receptor-mediated immune regulation adds an exogenous immunomodulatory layer to subjects already on potent immunosuppressive regimens; the combined immune system activity has not been characterized. Limited / unverified
- Known hypersensitivity to BPC-157, TB-500, KPV (Lys-Pro-Val), GHK-Cu, or formulation excipients. Limited / unverified
- Severe hepatic impairment: copper processing limitation applies identically to KLOW as GLOW. Limited / unverified
- Pregnancy: the combined angiogenic, immune-modulatory (KPV), and copper-delivering activity of KLOW has not been evaluated during pregnancy. Limited / unverified
- History of copper toxicity: previous copper sensitivity contraindicates the GHK-Cu component. Limited / unverified
- Active infectious disease requiring antimicrobial management: KPV's NF-κB suppression and pro-inflammatory cytokine reduction could modestly attenuate the acute-phase inflammatory response that is part of the innate immune defense against active infection; KLOW is appropriate for post-infectious repair and maintenance and should not be used during an active systemic infection. Limited / unverified
Side effects (limited evidence)
- Injection site redness and welting: more pronounced than GLOW in some subjects; the addition of KPV adds a fourth peptide to the injection bolus and KPV's MC1R activation in local skin can produce mild cutaneous vasodilation at the injection site; typically resolves within 1-2 hours. Limited / unverified
- Mild fatigue: attributable to the BPC-157/TB-500 dopaminergic modulation component; similar in character and duration to GLOW; typically mild and lasting 1-3 hours post-injection. Limited / unverified
- Zinc depletion: the same critical monitoring parameter as GLOW; mandatory zinc supplementation throughout all KLOW cycles. Limited / unverified
- Mild copper accumulation risk: identical to GLOW; the 5-days-on protocol and cycle limits mitigate this risk at standard doses. Limited / unverified
- Mild pigmentary changes (uncommon): KPV as an alpha-MSH receptor agonist has very modest melanocyte-stimulating activity compared to full-length alpha-MSH or Melanotan; mild, transient, and far less pronounced than Melanotan-1 or -2; not expected at the 400mcg/day KPV doses in KLOW but represents a theoretical consideration for subjects with existing pigmentation conditions. Limited / unverified
- Transient blood pressure changes: KPV's vasodilatory activity at MC receptors in vascular endothelium may produce mild transient blood pressure fluctuations in the first days of a cycle; typically self-limiting. Limited / unverified
- Anhedonia (rare): same BPC-157 dopaminergic mechanism as GLOW; rare; typically transient. Limited / unverified
- Mild nausea in first cycle days: occasionally reported with the four-peptide combination; mechanism may involve KPV's area postrema MC receptor interaction; typically resolves within the first week. Limited / unverified
- Elevated liver enzymes (ALT/AST): same hepatic copper processing consideration as GLOW; monitor in subjects with pre-existing liver conditions. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
BPC-157TB-500 (Thymosin Beta-4)KPVGHK-Cu (Copper Tripeptide-1)GLOW (BPC-157 + TB-500 + GHK-Cu)tri-heal-blend